In the article that accompanies this editorial, Smith et al 9 examine the association between availability of molecular testing before treatment decisions and outcomes such as time to next treatment ...

SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

Camryn was diagnosed with a low-grade glioma at age two after her parents noticed a lazy eye. Sixteen years, 11 brain surgeries and over six years of chemotherapy treatment, Camryn is now ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Molecular testing is transforming post-transplant care, reducing the need for invasive biopsies and personalizing medication regimens to lower the risk of infection and other downstream side effects, ...

Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...

Many pathology groups have a common misunderstanding when expanding into molecular testing: underestimating the operational burden of later ...

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates. Regular exercise is no longer just a recommendation for general health; it is now a ...

3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...

To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...